Olarigen (Olaparib)150Mg
0.00$
Olarigen tablets, comprising 150mg of Olaparib, serve as a therapeutic agent within oncology, primarily targeting specific cancer types like ovarian cancer, breast cancer, and prostate cancer. Falling under the category of poly (ADP-ribose) polymerase (PARP) inhibitors, Olaparib functions by impeding an enzyme crucial for repairing DNA damage within cancer cells. Healthcare providers prescribe Olarigen tablets as a component of a holistic treatment approach for patients fitting the criteria with these particular cancer types.
Indication:
Olarigen tablets, containing 150mg of Olaparib, are prescribed for treating specific cancers like ovarian, breast, and prostate cancer.
Pharmacology:
Olaparib, the active component in Olarigen tablets, acts as a poly (ADP-ribose) polymerase (PARP) inhibitor. It functions by obstructing the PARP enzyme, vital for repairing DNA damage in cancer cells. By impeding this repair process, Olaparib helps hinder cancer cells from self-repairing, leading to their eventual demise.
Dosage and Administration:
The recommended dosage of Olarigen tablets is typically taken orally, with or without food, following healthcare provider’s instructions. The precise dosage may vary based on individual patient factors like cancer type and stage. Patients should adhere to the prescribed dosage regimen.
Interaction:
Olarigen may interact with various medications, including other chemotherapy drugs and those metabolized by cytochrome P450 enzymes. Patients should inform their healthcare provider about all medications, supplements, and herbal products they are taking to avoid potential interactions.
Side Effects:
Common side effects of Olarigen tablets may include nausea, vomiting, fatigue, diarrhea, and decreased appetite. Severe side effects like bone marrow suppression, increased infection risk, and lung issues may also occur. Patients should promptly report any severe or persistent side effects to their healthcare provider.
Precautions and Warnings:
Patients on Olarigen tablets should undergo regular monitoring for potential adverse reactions, particularly bone marrow suppression and lung issues. Olaparib may harm the fetus if used during pregnancy, necessitating contraception during and after treatment. Breastfeeding is not recommended while taking Olarigen.
Overdose Effects:
In case of overdose with Olarigen tablets, patients may experience intensified adverse effects such as bone marrow suppression and heightened infection risk. Management typically involves supportive care and monitoring for complications. Immediate medical attention is recommended if overdose is suspected.
Product Name | Olarigen 150 Mg |
---|---|
Generic Name | Olaparib |
Formulation | Tablet |
Available Pack Size | 120's |
Available Strength | 150 |
Reviews
There are no reviews yet.